ATyr Pharma Announces Second Fast Track Designation For Efzofitimod Clinical Program

aTyr Pharma, Inc. (LIFE) announced the FDA has granted the company Fast Track designation for efzofitimod, for the treatment of systemic sclerosis-associated, interstitial lung disease. Efzofitimod previously received orphan drug designation for systemic sclerosis.

aTyr is developing efzofitimod as a potential therapeutic for patients with fibrotic lung disease. It is a first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states via selective modulation of neuropilin-2. The company is currently investigating efzofitimod in patients with pulmonary sarcoidosis in a global phase 3 study called EFZO-FIT.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT